Table 3.

Randomized Phase II trials of induction chemotherapy and RT compared to RT alone

Study (authors or trial)	Median follow-up (months)	Time point (years)	Treatment arm	N	Regimen	OS (%)	PFS (%)	DMFS (%)	Ref
Chan et al (Hong Kong)	28.5	2	RT	40	66 Gy ± 7.5 Gy boost	80	72	76	15
			Induction-RTadjuvant chemo	37	CDDP 100 mg/m2 + 5-FU 1000 mg/m2	80	68	78
					2 cycles induction
					4 cycles adjuvant
						NS	NS	NS
International Nasopharynx	49	5	RT	168	70 Gy	46	30		16
Cancer Study Group			Induction-RT	171	BEC	40	40
VUMCA I					3 cycles
						NS	P < 0.01	SS
Chua et al (AOCOA)	30	3	RT	152	66–74 Gy	71	42		18
			Induction-RT	134	CDDP 60 mg/m2 + Epi 110 mg/m2	78	48
					2–3 cycles
						NS	NS	NS
Ma et al (Guangzhou)	62	5	RT	225	68–72 Gy ± 10–14 Gy boost w/EBRT or 20–24 Gy boost w/HDR	56	49	75	17
			Induction-RT	224	CDDP, 5-FU, Bleo	63	59	79
					2–3 cycles
						NS	P = 0.05	NS
Hareyama et al (Japan)	49	5	RT	40	66–68 Gy	48	43	56	20
			Induction-RT	40	CDDP 80 mg/m2 + 5-FU 800 mg/m2	60	55	74
					2 cycles
						NS	NS	NS

Abbreviations: 5-FU, 5-fluorouracil; AOCOA, Asian-Oceanian Clinical Oncology Association; BEC, bleomycin, epirubicin, and cisplatin; Bleo, bleomycin; CDDP, cisplatin; EBRT, External Beam Radiotherapy; Epi, epirubicin; Gy, Gray; HDR, high dose rate; OS, overall survival; PFS, progression-free survival; PWH, Prince of Wales Hospital; RT, ratiotheraphy; NS, not significant; DMFS; distant metastases-free survival.